Catalyst Biosciences
Exceptional Science. Essential Medicines.

Anti-Complement (C3) for Dry AMD
OIS@ASRS
8 August 2016
Anti-C3 Proteases for Dry AMD (GA)

- **Advantages of Protease versus Antibody or small molecule drugs**
  - **Catalytic versus Stoichiometric Mechanism of Action**
    - Unlike stoichiometric drugs, proteases will maintain effective regulation at concentrations significantly below the target concentration.
    - Enhanced duration of action expected to allow decreased dosing frequency.

- **Advantages of C3 as Target**
  - C3 inhibition blocks all arms of the complement cascade and prevents formation of anaphylotoxins and other pro-inflammatory mediators as well as the membrane attack complex (MAC).
Catalyst Dry AMD (GA) Program

• Use proprietary selection/counter-selection technologies to create orthogonal anti-C3 leads based on two distinct human proteases (u-PA & MTSP-1)

• Target Product Profile
  – ≤ 6 mutations
  – C3 knockdown in vitreous ≥95% at 10 days and ≥75% at 20 days (equivalent to every two months in man) after single dose in cynomolgus monkeys
  – No ocular toxicity at efficacious dose (therapeutic index testing limit is 6-8 with current formulation)
Anti-C3 Dry AMD Program: Toxicity Study

- Comprehensive, non-human primate single dose escalation ocular safety/toxicity study completed for advanced MTSP-1 & u-PA based leads
  - Three intravitreal doses (12.5, 37.5, or 125 µg/eye)
  - Right eye received test article; left eye injected with vehicle control
  - “Clinical observations”, food consumption, etc.
  - Ophthalmic examinations: slit-lamp biomicroscopy and indirect ophthalmoscope observations, followed by color fundus photography or optical coherence tomography (OCT) prior to dosing and on days 2, 8, and 15 post-dosing
- No observations for one of two molecules tested for both u-PA and MTSP-1 based leads
Single Dose Cyno Ocular PK (vitreous)

\[ [u-PA \text{ lead}] \text{ (µM)} \]

\[ t_{1/2} = 1.9 \text{ days, 1.6 days} \]

\[ \text{In vivo recovery} = 78\%, 73\% \]

\[ [MTSP-1 \text{ lead}] \text{ (µM)} \]

\[ t_{1/2} = 1.7 \text{ days, 1.7 days} \]

\[ \text{In vivo recovery} = 100\%, 18\% \]
Results of two different experiments for each novel protease are plotted. Time points for experiment 1 were 0, 1, 2, and 6 days. Time points for experiment 2 were 0, 1, 7, and 28 days.
AMD Program Summary

- Catalyst anti-C3 leads are potent, stable, and well tolerated in a NHP model
  - Anti-complement leads inactivate ~5 to > 1100 human C3 molecules per hour
  - NOAEL in NHP model appears to be ≥ 125 µg for both current lead molecules (equivalent to ≥ 375 µg/eye in man)
  - 2 duration of action studies in NHP model suggest complete inhibition of C3 beyond 7 days post dosing but modest to no inhibition at 28 days (equivalent to 21 and 84 days in man)
- Catalyst anti-C3 leads expected to be differentiated from antibody and small molecule competitors
  - Catalytic turnover of target and pegylation or “full-length” protease constructs to improve PK expected to allow significantly less frequent dosing than isolated protease domains

WT MTSP-1 89kD

N* C
Catalyst Biosciences
Exceptional Science. Essential Medicines.

www.catalystbiosciences.com